FDA Clearance Tracker · P960007-S015
TRANSCYTE/HUMAN FIBROBLAST DERIVED TEMPORARY SKIN SUBSTITUTE
Last checked: Nov 20, 2026Latest source record: Aug 30, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Aug 30, 2001
Approved
Time to decision
65 days
Received Jun 26, 2001. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P960007-S015
- Device name
- TRANSCYTE/HUMAN FIBROBLAST DERIVED TEMPORARY SKIN SUBSTITUTE
- Applicant
- Shire Regenerative Medicine
- Applicant location
- San Diego, CA
- Received
- Jun 26, 2001
- Decided
- Aug 30, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P960007
Device type
- Device type
- Dressing, wound and burn, interactive (MGR)
- Device class
- Class III
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR AMENDED LABELING TO INCLUDE INFORMATION REGARDING THE RESULTS OF TESTING THE DONOR MOTHER'S SERA FOR VIRUSES AND OTHER INFECTIOUS AGENTS.
Source documents
Other decisions for Shire Regenerative Medicine
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.